Venezuelan equine encephalitis virus E2 glycoprotein (E2 glycoprotein (VEEV))

The Venezuelan equine encephalitis virus E2 glycoprotein is a structural envelope protein essential for viral attachment to host cells, acting as the primary mediator of host receptor binding—specifically to LDLRAD3 (Low Density Lipoprotein Receptor Class A Domain Containing 3)[6][3]. E2 forms heterodimers with E1; E1 mediates membrane fusion, while E2 determines cellular tropism and contains dominant neutralizing epitopes, making it a main target for neutralizing antibodies and vaccine development[1][3]. E2 is also a determinant of viral host range and pathogenesis: amino acid alterations in E2 can lead to changes in species susceptibility, epidemic potential, and mouse/horse virulence[2][3]. Despite extensive research, there are no approved therapeutic drugs directly targeting E2, but virus-neutralizing monoclonal antibodies and peptide vaccines have shown protective effects in animal models[1][3]. E2 is a primary antigenic determinant for diagnostic serology and a critical protein in the life cycle and epidemiology of Venezuelan equine encephalitis virus, a zoonotic alphavirus causing neuroinvasive disease in humans and horses[5][6]. If more structured drug-target pharmacology or pathway data are needed, this information can be expanded as new therapeutic agents targeting E2 progress through preclinical or clinical development.

Other names

VEEV E2 glycoproteinE2 protein (VEEV)Envelope glycoprotein E2

Inhibits viral entry via blocking E2–host receptor interaction[1][3][6]; Neutralizes virus by targeting specific epitopes on E2[1][3]; Prevents viral membrane fusion indirectly through antibody binding[3]; Other